Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)
Keros Therapeutics posted quarterly Free Cash Flow of -$25.9 million for Q4 2025, up 44.1% year-on-year from -$18.0 million in Q4 2024, and down 1501.95% on a QoQ basis from $1.8 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Free Cash Flow data on file, last reported at -$25.9 million in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 44.1% year-over-year to -$25.9 million; the trailing twelve-month figure through Dec 2025 stood at $107.5 million (up 166.03% YoY), and the FY2025 full-year result was $107.5 million, up 166.03% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$25.9 million, down from $1.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $160.6 million in Q1 2025 and bottomed at -$46.3 million in Q4 2024.
- The 5-year median for Free Cash Flow is -$25.2 million (2022), against an average of -$15.7 million.
- The widest annual swing landed in 2023, when Free Cash Flow tumbled 2162.62%; it then soared 458.58% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$19.7 million in 2021, then slipped by 14.94% to -$22.7 million in 2022, then declined by 14.68% to -$26.0 million in 2023, then tumbled by 78.08% to -$46.3 million in 2024, then soared by 44.1% to -$25.9 million in 2025.
- The last three Free Cash Flow figures came in at -$25.9 million (Q4 2025), $1.8 million (Q3 2025), and -$29.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -25.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25.88 Mn |
| Dec 31, 2025 | -25.88 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | -29.07 Mn |
| Jun 30, 2025 | -29.07 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -39.66 Mn |
| Jun 30, 2024 | -39.66 Mn |
| Mar 31, 2024 | -44.79 Mn |
| Mar 31, 2024 | -44.79 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Sep 30, 2023 | -32.67 Mn |
| Sep 30, 2023 | -32.67 Mn |
| Jun 30, 2023 | -32.18 Mn |
| Jun 30, 2023 | -32.18 Mn |
| Mar 31, 2023 | -34.26 Mn |
| Mar 31, 2023 | -34.26 Mn |
| Dec 31, 2022 | -22.67 Mn |
| Dec 31, 2022 | -22.67 Mn |
| Sep 30, 2022 | -24.59 Mn |
| Sep 30, 2022 | -24.59 Mn |
| Jun 30, 2022 | -22.53 Mn |
| Jun 30, 2022 | -22.53 Mn |
| Mar 31, 2022 | -1.51 Mn |
| Mar 31, 2022 | -1.51 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Sep 30, 2021 | -14.59 Mn |
| Sep 30, 2021 | -14.59 Mn |
| Jun 30, 2021 | -18.36 Mn |
| Jun 30, 2021 | -18.36 Mn |
| Mar 31, 2021 | -10.51 Mn |
| Mar 31, 2021 | -10.51 Mn |
| Dec 31, 2020 | -8.05 Mn |
| Dec 31, 2020 | -8.05 Mn |
| Sep 30, 2020 | -10.89 Mn |
| Sep 30, 2020 | -10.89 Mn |
| Jun 30, 2020 | -9.96 Mn |
| Jun 30, 2020 | -9.96 Mn |
| Mar 31, 2020 | -8.30 Mn |
| Mar 31, 2020 | -8.30 Mn |
| Dec 31, 2019 | -5.52 Mn |
| Dec 31, 2019 | -5.52 Mn |
| Sep 30, 2019 | -3.04 Mn |
| Sep 30, 2019 | -3.04 Mn |
| Jun 30, 2019 | -5.20 Mn |
| Jun 30, 2019 | -5.20 Mn |
| Mar 31, 2019 | -2.51 Mn |
| Mar 31, 2019 | -2.51 Mn |